Medical treatments of elderly, French patients with type 2 diabetes: results at inclusion in the GERODIAB Cohort - PubMed (original) (raw)
Observational Study
doi: 10.1111/fcp.12160. Epub 2015 Nov 8.
Collaborators, Affiliations
- PMID: 26478566
- DOI: 10.1111/fcp.12160
Observational Study
Medical treatments of elderly, French patients with type 2 diabetes: results at inclusion in the GERODIAB Cohort
Jean A Doucet et al. Fundam Clin Pharmacol. 2016 Feb.
Abstract
Prevalence of diabetes in the elderly increases, and half of the French diabetics are over the age of 75 years. The GERODIAB study is the first French multicentre, prospective, observational study designed to analyse over 5 years the influence of glycaemic control on morbidity-mortality in type 2 diabetics patients 70 years old and over. This study analysed the diabetic and geriatric factors associated with the treatment modalities, particularly insulin, at inclusion in the cohort. The cohort of 987 type 2 diabetics was divided into three groups according to the method of treatment. Slightly fewer than one-third of these patients (26.4%) were treated with insulin alone, 31% received insulin and oral antidiabetic drugs, and 42.7% oral antidiabetic drugs alone. The patients that received insulin alone were significantly older, had poorer glycaemic control (HbA1c = 7.9 ± 1.4, 7.8 ± 1.0 and 7.1 ± 1.2%, respectively; P < 0.001) and had greater alterations of glomerular filtration rate (GFR). HbA1c was below 6.5% in 15% of patients and 37.3% of patients had a GFR below 60 mL/min. The patients treated with insulin alone had significantly more hypoglycaemic episodes (respectively 53.3, 36.3 and 19.5%, P < 0.001), retinopathy, cardiovascular involvement and more specific geriatric complications, such as cognitive disorders (respectively 34.1, 31.4 and 23.6%, P = 0.006). In this specific population of elderly type 2 diabetic patients, diabetic and geriatric conditions significantly differed between the types of drug treatments. Considering low values of HbA1c and GFR, some patients seemed overtreated and other patients received inappropriate drugs.
Keywords: GERODIAB; ageing; insulin; oral antidiabetic drugs; type 2 diabetes.
© 2015 Société Française de Pharmacologie et de Thérapeutique.
Similar articles
- Five-Year Follow-Up of Diabetic Complications and Geriatric Alterations in French Older Patients with Type 2 Diabetes According to Treatment Modalities: The Observational Prospective GERODIAB Cohort.
Doucet J, Guérin O, Hilbert C, Bordier L, Wils J, Bénichou J, Bauduceau B. Doucet J, et al. Drugs Aging. 2023 Nov;40(11):1027-1036. doi: 10.1007/s40266-023-01067-9. Epub 2023 Oct 18. Drugs Aging. 2023. PMID: 37851296 - Inadequate Glycaemic Control and Therapeutic Management of Adults over 65 Years Old with Type 2 Diabetes Mellitus in Spain.
Formiga F, Franch-Nadal J, Rodriguez L, Ávila L, Fuster E. Formiga F, et al. J Nutr Health Aging. 2017;21(10):1365-1370. doi: 10.1007/s12603-017-0869-4. J Nutr Health Aging. 2017. PMID: 29188902 - GERODIAB: Glycaemic control and 5-year morbidity/mortality of type 2 diabetic patients aged 70 years and older: 1. Description of the population at inclusion.
Doucet J, Le Floch JP, Bauduceau B, Verny C; SFD/SFGG Intergroup. Doucet J, et al. Diabetes Metab. 2012 Dec;38(6):523-30. doi: 10.1016/j.diabet.2012.07.001. Epub 2012 Oct 10. Diabetes Metab. 2012. PMID: 23062595 - Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review. - Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL, Figgitt DP. Plosker GL, et al. Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
Cited by
- Diabetes and Frail Older Patients: Glycemic Control and Prescription Profile in Real Life.
Mangé AS, Pagès A, Sourdet S, Cestac P, McCambridge C. Mangé AS, et al. Pharmacy (Basel). 2021 Jun 22;9(3):115. doi: 10.3390/pharmacy9030115. Pharmacy (Basel). 2021. PMID: 34206422 Free PMC article. - People with type 2 diabetes and screen-detected cognitive impairment use acute health care services more often: observations from the COG-ID study.
Janssen J, Koekkoek PS, Biessels GJ, Kappelle LJ, Rutten GEHM; Cog-ID study group. Janssen J, et al. Diabetol Metab Syndr. 2019 Feb 22;11:21. doi: 10.1186/s13098-019-0416-z. eCollection 2019. Diabetol Metab Syndr. 2019. PMID: 30833988 Free PMC article. - Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017.
Einarson TR, Acs A, Ludwig C, Panton UH. Einarson TR, et al. Cardiovasc Diabetol. 2018 Jun 8;17(1):83. doi: 10.1186/s12933-018-0728-6. Cardiovasc Diabetol. 2018. PMID: 29884191 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical